Clinical trials / NCT02682407
NCT02682407Phase 2Terminated

Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

Study sponsor: Omeros Corporation

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2020-08-25Actual
Enrollment · participants31Actual
Source updated2026-03-30Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 6 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Cohort 1-3: Proportion of IgAN, LN, MN, C3 Glomerulopathy subjects with treatment related adverse events (AE). Measure: Cohort 4: Proportion of IgAN patients of Asian descent with treatment related AEs. Measure: Cohort 4: Change from baseline in serum and urine complement component levels.

+ After

Measure: Cohort 1-3: Proportion of IgAN, LN, MN, C3 Glomerulopathy Participants With Treatment Related Adverse Events (AE). Measure: Cohort 4: Proportion of IgAN Participants of Asian Descent With Treatment Related AEs. Measure: Cohort 4: Change From Baseline in Serum and Urine Complement Component Levels.

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

54 participants (planned)

+ After

31 participants (actual)

Completion date type changed

− Before

Estimated

+ After

Actual

Primary completion date changed

− Before

Dec 2020

+ After

25 Aug 2020

Recruitment status changed

− Before

Recruiting

+ After

Terminated

Check registry source